We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Avian Cell Line DuckCelt ® -T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac ®.
- Authors
Chupin, Caroline; Pizzorno, Andrés; Traversier, Aurélien; Brun, Pauline; Ogonczyk-Makowska, Daniela; Padey, Blandine; Milesi, Cédrine; Dulière, Victoria; Laurent, Emilie; Julien, Thomas; Galloux, Marie; Lina, Bruno; Eléouët, Jean-François; Moreau, Karen; Hamelin, Marie-Eve; Terrier, Olivier; Boivin, Guy; Dubois, Julia; Rosa-Calatrava, Manuel
- Abstract
The development of a live-attenuated vaccine (LAV) for the prevention of human metapneumovirus (HMPV) infection is often hampered by the lack of highly efficient and scalable cell-based production systems that support eventual global vaccine production. Avian cell lines cultivated in suspension compete with traditional cell platforms used for viral vaccine manufacture. We investigated whether the DuckCelt®-T17 avian cell line (Vaxxel), previously described as an efficient production system for several influenza strains, could also be used to produce a new HMPV LAV candidate (Metavac®, SH gene-deleted A1/C-85473 HMPV). To that end, we characterized the operational parameters of MOI, cell density, and trypsin addition to achieve the optimal production of Metavac®, and demonstrated that the DuckCelt®-T17 cell line is permissive and well-adapted to the production of the wild-type A1/C-85473 HMPV and the Metavac® vaccine candidate. Moreover, our results confirmed that the LAV candidate produced in DuckCelt®-T17 cells conserves its advantageous replication properties in LLC-MK2 and 3D-reconstituted human airway epithelium models, and its capacity to induce efficient neutralizing antibodies in a BALB/c mouse model. Our results suggest that the DuckCelt®-T17 avian cell line is a very promising platform for the scalable in-suspension serum-free production of the HMPV-based LAV candidate Metavac®.
- Subjects
CELL lines; LABORATORY mice; VIRAL vaccines; VACCINE manufacturing; VACCINES
- Publication
Vaccines, 2021, Vol 9, Issue 10, p1190
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines9101190